BC 819

Drug Profile

BC 819

Alternative Names: BC-819; DTA-H19; DTA-H19/PEI

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioCancell Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer
  • No development reported Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Nov 2017 Final efficacy and adverse events data from a phase IIb trial in Bladder cancer released by BioCanCell
  • 14 Aug 2017 BioCancell Therapeutics plans two registrational trials for Bladder cancer
  • 01 Oct 2015 Efficacy and adverse events data from a phase I trial in Bladder cancer released by BioCancell Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top